Top

Gepubliceerd in:

2021 | OriginalPaper | Hoofdstuk

2. Medische diagnostiek

Auteurs : Robert Damstra, PhD, MD, Kristiana Gordon, PhD, MD, Malou van Zanten, PhD, PT, Sahar Mansour, PhD, MD, Kirsten van Duinen, MD, Sarah Thomis, MSc, Nele Devoogdt, PhD, PT, Inge Fourneau, PhD, MD, Sjan Lavrijsen, PhD, MD, Wendemagegn Enbiale, MD, Michette de Rooij, PhD, MD

Gepubliceerd in: Oedeem en oedeemtherapie

Uitgeverij: Bohn Stafleu van Loghum

Samenvatting

Medische diagnostiek vormt de basis voor de analyse van zwelling. Er wordt veel aandacht besteed aan de aspecten rond secundair lymfoedeem, mede in relatie met het uitlokkend moment, zoals een oncologische behandeling, filariasis, podoconiosis, erysipelas of overgewicht. Ook wordt besproken dat primair lymfoedeem geen diagnose is en de oude (tijdsgebonden) indeling in congenitaal, precox en tarda wordt verlaten. Middels een speciaal algoritme wordt de work-up bij verdenking van aangeboren lymfoedeem/vasculaire malformatie gepresenteerd waarbij de verschillende genetische afwijkingen worden doorgenomen. Zorgvuldige feno- en genotypering zijn hierbij essentieel. Ook kan zwelling door een veneuze pathologie worden verklaard. Door een systematische benadering van anamnese, lichamelijk en aanvullend onderzoek krijgt u een helder en praktisch beeld van de medische diagnostiek van zwelling. Er is een speciaal hoofdstuk voor huidafwijkingen bij en door lymfoedeem. Het hele hoofdstuk is rijk geïllustreerd met fotomateriaal.

vorige hoofdstuk Anatomie en fysiologie

volgende hoofdstuk Terminologie en zorgmodellen voor mensen met chronische aandoeningen

Moffatt CJ, Keeley V, Franks PJ, et al. Chronic oedema: a prevalent health care problem for UK health services. Int Wound J. 2017;14(5):772–81. https://doi.org/10.1111/iwj.12694 [published Online First: 2016/12/06].

Mortimer PS, Levick JR. Chronic peripheral oedema: the critical role of the lymphatic system. Clin Med (Lond). 2004;4(5):448–53. https://doi.org/10.7861/clinmedicine.4-5-448 [published Online First: 2004/11/13].

Angeli V, Randolph GJ. Inflammation, lymphatic function, and dendritic cell migration. Lymphat Res Biol. 2006;4(4):217–28. https://doi.org/10.1089/lrb.2006.4406 [published Online First: 2007/03/31].

Tso P, Balint JA. Formation and transport of chylomicrons by enterocytes to the lymphatics. Am J Physiol. 1986;250(6 Pt 1):G715–26. https://doi.org/10.1152/ajpgi.1986.250.6.g715 [published Online First: 1986/06/01].

Levick JR, Michel CC. Microvascular fluid exchange and the revised Starling principle. Cardiovasc Res. 2010;87(2):198–210. https://doi.org/10.1093/cvr/cvq062 [published Online First: 2010/03/05].

International Society of L. The diagnosis and treatment of peripheral lymphedema: 2013 Consensus Document of the International Society of Lymphology. Lymphology 2013;46(1):1–11 [published Online First: 2013/08/13].

Halk AB, Damstra RJ. First Dutch guidelines on lipedema using the international classification of functioning, disability and health. Phlebology. 2017;32(3):152–59. https://doi.org/10.1177/0268355516639421 [published Online First: 2016/04/15].

Bertsch T, Erbacher G, Corda D, et al. European best practice of lipedema. European Best Practice of Lipedema. Phlebologie. 2020.

Gloviczki P, Driscoll DJ. Klippel-Trenaunay syndrome: current management. Phlebology. 2007;22(6):291–8.

10.

Brakenhielm E, Alitalo K. Cardiac lymphatics in health and disease. Nat Rev Cardiol. 2019;16(1):56–68. https://doi.org/10.1038/s41569-018-0087-8 [published Online First: 2018/10/20].

11.

Tamura R, Yoshida K, Toda M. Current understanding of lymphatic vessels in the central nervous system. Neurosurg Rev. 2019. https://doi.org/10.1007/s10143-019-01133-0 [published Online First: 2019/06/19].

12.

Vannelli A, Battaglia L, Poiasina E, et al. Pelvic lymphedema: truth or fiction? Med Hypotheses. 2009;72(3):267–70. https://doi.org/10.1016/j.mehy.2008.10.019 [published Online First: 2008/12/17].

13.

Miest RY, Bruce AJ, Comfere NI, et al. A diagnostic approach to recurrent orofacial swelling: a retrospective study of 104 patients. Mayo Clin Proc. 2017;92(7):1053–60. https://doi.org/10.1016/j.mayocp.2017.03.015 [published Online First: 2017/06/12].

14.

Eber AE, Mlacker S, Verne S, et al. Morbihan disease complicated by dermatosis neglecta: an unique presentation. J Cutan Pathol. 2017;44(5):470–73. https://doi.org/10.1111/cup.12902 [published Online First: 2017/01/18].

15.

Nozicka Z. Endovasal granulomatous lymphangiitis as a pathogenetic factor in cheilitis granulomatosa. J Oral Pathol. 1985;14(5):363–5. https://doi.org/10.1111/j.1600-0714.1985.tb00506.x [published Online First: 1985/05/01].

16.

White MI, Smart LM, Macgregor DM, et al. Recurrent facial oedema associated with a silicone-rubber implant. Br J Dermatol. 1991;125(2):183–5. https://doi.org/10.1111/j.1365-2133.1991.tb06069.x [published Online First: 1991/08/01].

17.

Saha M, Edmonds E, Martin J, et al. Penile lymphoedema in association with asymptomatic Crohn’s disease. Clin Exp Dermatol. 2009;34(1):88–90. https://doi.org/10.1111/j.1365-2230.2008.02762.x [published Online First: 2008/12/17].

18.

Huang Q, Ge BJ, Liu LM, et al. Successful management of chylous ascites with total parenteral nutrition, somatostatin, and fibrin glue. Chin Med J (Engl). 2007;120(20):1847–9 [published Online First: 2007/11/22].

19.

Chamouard P, Nehme-Schuster H, Simler JM, et al. Videocapsule endoscopy is useful for the diagnosis of intestinal lymphangiectasia. Dig Liver Dis. 2006;38(9):699–703. https://doi.org/10.1016/j.dld.2006.01.027 [published Online First: 2006/03/11].

20.

Lund RH, Moritz MW. Complications of Denver peritoneovenous shunting. Arch Surg. 1982;117(7):924–8. https://doi.org/10.1001/archsurg.1982.01380310038009 [published Online First: 1982/07/01].

21.

Sarica M, Gordon K, Van Zanten M, et al. Lymphoscintigraphic abnormalities associated with milroy disease and lymphedema-distichiasis syndrome. Lymphat Res Biol. 2019;17(6):610–19. https://doi.org/10.1089/lrb.2019.0016 [published Online First: 2019/11/14].

22.

Connell FC, Gordon K, Brice G, et al. The classification and diagnostic algorithm for primary lymphatic dysplasia: an update from 2010 to include molecular findings. Clin Genet. 2013;84(4):303–14. https://doi.org/10.1111/cge.12173 [published Online First: 2013/04/30].

23.

Gordon K, Varney R, Keeley V, et al. Update and audit of the St George’s classification algorithm of primary lymphatic anomalies: a clinical and molecular approach to diagnosis. J Med Genet. 2020. https://doi.org/10.1136/jmedgenet-2019-106084 [published Online First: 2020/05/16].

24.

Atton G, Gordon K, Brice G, et al. The lymphatic phenotype in Turner syndrome: an evaluation of nineteen patients and literature review. Eur J Hum Genet. 2015;23(12):1634–9. https://doi.org/10.1038/ejhg.2015.41 [published Online First: 2015/03/26].

25.

Joyce S, Gordon K, Brice G, et al. The lymphatic phenotype in Noonan and Cardiofaciocutaneous syndrome. Eur J Hum Genet. 2016;24(5):690–6. https://doi.org/10.1038/ejhg.2015.175 [published Online First: 2015/08/06].

26.

Ostergaard P, Simpson MA, Mendola A, et al. Mutations in KIF11 cause autosomal-dominant microcephaly variably associated with congenital lymphedema and chorioretinopathy. Am J Hum Genet. 2012;90(2):356–62. https://doi.org/10.1016/j.ajhg.2011.12.018 [published Online First: 2012/01/31].

27.

Jones GE, Ostergaard P, Moore AT, et al. Microcephaly with or without chorioretinopathy, lymphoedema, or mental retardation (MCLMR): review of phenotype associated with KIF11 mutations. Eur J Hum Genet. 2014;22(7):881–7. https://doi.org/10.1038/ejhg.2013.263 [published Online First: 2013/11/28].

28.

Fotiou E, Martin-Almedina S, Simpson MA, et al. Novel mutations in PIEZO1 cause an autosomal recessive generalized lymphatic dysplasia with non-immune hydrops fetalis. Nat Commun. 2015;6:8085. https://doi.org/10.1038/ncomms9085 [published Online First: 2015/09/04].

29.

Martin-Almedina S, Martinez-Corral I, Holdhus R, et al. EPHB4 kinase-inactivating mutations cause autosomal dominant lymphatic-related hydrops fetalis. J Clin Invest. 2016;126(8):3080–8. https://doi.org/10.1172/jci85794 [published Online First: 2016/07/12].

30.

Brice GW, Mansour S, Ostergaard P, et al. Milroy Disease. 2014.

31.

Irrthum A, Karkkainen MJ, Devriendt K, et al. Congenital hereditary lymphedema caused by a mutation that inactivates VEGFR3 tyrosine kinase. Am J Hum Genet. 2000;67(2):295–301. https://doi.org/10.1086/303019 [published Online First: 2000/06/17].

32.

Gordon K, Schulte D, Brice G, et al. Mutation in vascular endothelial growth factor-C, a ligand for vascular endothelial growth factor receptor-3, is associated with autosomal dominant milroy-like primary lymphedema. Circ Res. 2013;112(6):956–60. https://doi.org/10.1161/circresaha.113.300350 [published Online First: 2013/02/16].

33.

Brice G, Mansour S, Bell R, et al. Analysis of the phenotypic abnormalities in lymphoedema-distichiasis syndrome in 74 patients with FOXC2 mutations or linkage to 16q24. J Med Genet. 2002;39(7):478–83. https://doi.org/10.1136/jmg.39.7.478 [published Online First: 2002/07/13].

34.

Fang J, Dagenais SL, Erickson RP, et al. Mutations in FOXC2 (MFH-1), a forkhead family transcription factor, are responsible for the hereditary lymphedema-distichiasis syndrome. Am J Hum Genet. 2000;67(6):1382–8. https://doi.org/10.1086/316915 [published Online First: 2000/11/15].

35.

Ostergaard P, Simpson MA, Connell FC, et al. Mutations in GATA2 cause primary lymphedema associated with a predisposition to acute myeloid leukemia (Emberger syndrome). Nat Genet. 2011;43(10):929–31. https://doi.org/10.1038/ng.923 [published Online First: 2011/09/06].

36.

Ferrell RE, Baty CJ, Kimak MA, et al. GJC2 missense mutations cause human lymphedema. Am J Hum Genet. 2010;86(6):943–8. https://doi.org/10.1016/j.ajhg.2010.04.010 [published Online First: 2010/06/12].

37.

Ostergaard P, Simpson MA, Brice G, et al. Rapid identification of mutations in GJC2 in primary lymphoedema using whole exome sequencing combined with linkage analysis with delineation of the phenotype. J Med Genet. 2011;48(4):251–5. https://doi.org/10.1136/jmg.2010.085563 [published Online First: 2011/01/27].

38.

Keppler-Noreuil KM, Sapp JC, Lindhurst MJ, et al. Clinical delineation and natural history of the PIK3CA-related overgrowth spectrum. Am J Med Genet A. 2014;164A(7):1713–33. https://doi.org/10.1002/ajmg.a.36552 [published Online First: 2014/05/02].

39.

Keppler-Noreuil KM, Rios JJ, Parker VE, et al. PIK3CA-related overgrowth spectrum (PROS): diagnostic and testing eligibility criteria, differential diagnosis, and evaluation. Am J Med Genet A. 2015;167A(2):287–95. https://doi.org/10.1002/ajmg.a.36836 [published Online First: 2015/01/06].

40.

Herricks JR, Hotez PJ, Wanga V, et al. The global burden of disease study 2013: What does it mean for the NTDs? PLoS Negl Trop Dis. 2017;11(8):e0005424. https://doi.org/10.1371/journal.pntd.0005424 [published Online First: 2017/08/05].

41.

Nagai Y, Aoyama K, Endo Y, et al. Lymphedema of the extremities developed as the initial manifestation of rheumatoid arthritis. Eur J Dermatol. 2007;17(2):175–6.

42.

Sakorafas GH, Peros G, Cataliotti L, et al. Lymphedema following axillary lymph node dissection for breast cancer. Surg Oncol. 2006;15(3):153–65. https://doi.org/10.1016/j.suronc.2006.11.003 [published Online First: 2006/12/26].

43.

Stoberl C, Partsch H. [Erysipelas and lymphedema–egg or hen?]. Z Hautkr. 1987;62(1):56–62 [published Online First: 1987/01/01].

44.

DiSipio T, Rye S, Newman B, et al. Incidence of unilateral arm lymphoedema after breast cancer: a systematic review and meta-analysis. Lancet Oncol. 2013;14(6):500–15. https://doi.org/10.1016/S1470-2045(13)70076-7.CrossRefPubMed

45.

Finegold DN, Baty CJ, Knickelbein KZ, et al. Connexin 47 mutations increase risk for secondary lymphedema following breast cancer treatment. Clin Cancer Res. 2012;18(8):2382–90. https://doi.org/10.1158/1078-0432.ccr-11-2303 [published Online First: 2012/02/22].

46.

Damstra RJ, Mortimer PS. Diagnosis and therapy in children with lymphoedema. Phlebology. 2008;23(6):276–86. https://doi.org/10.1258/phleb.2008.008010 [published Online First: 2008/11/26].

47.

Kinmonth JB, Taylor GW, Tracy GD, et al. Primary lymphoedema; clinical and lymphangiographic studies of a series of 107 patients in which the lower limbs were affected. Br J Surg. 1957;45(189):1–9. https://doi.org/10.1002/bjs.18004518902 [published Online First: 1957/07/01].

48.

Partsch H, Stoberl C, Urbanek A, et al. Clinical use of indirect lymphography in different forms of leg edema. Lymphology. 1988;21(3):152–60 [published Online First: 1988/09/01].

49.

Itkin M. Lymphatic intervention is a new frontier of IR. J Vasc Interv Radiol. 2014;25(9):1404–5. https://doi.org/10.1016/j.jvir.2014.06.004 [published Online First: 2014/08/26].

50.

Hayashi A, Visconti G, Yamamoto T, et al. Intraoperative imaging of lymphatic vessel using ultra high-frequency ultrasound. J Plast Reconstr Aesthet Surg JPRAS. 2018;71(5):778–80. https://doi.org/10.1016/j.bjps.2018.01.013 [published Online First: 2018/02/06].

51.

Barrett T, Choyke PL, Kobayashi H. Imaging of the lymphatic system: new horizons. Contrast Media Mol Imag. 2006;1(6):230–45. https://doi.org/10.1002/cmmi.116 [published Online First: 2006/12/29].

52.

Lee BB, Andrade M, Antignani PL, et al. Diagnosis and treatment of primary lymphedema. Consensus document of the International Union of Phlebology (IUP)-2013. Int Angiol. 2013;32(6):541–74 [published Online First: 2013/11/12].

53.

White RD, Weir-McCall JR, Budak MJ, et al. Contrast-enhanced magnetic resonance lymphography in the assessment of lower limb lymphoedema. Clin Radiol. 2014;69(11):e435–44. https://doi.org/10.1016/j.crad.2014.06.007 [published Online First: 2014/07/30].

54.

Sherman AI, Ter-Pogossian M. Lymph-node concentration of radioactive colloidal gold following interstitial injection. Cancer. 1953;6(6):1238–40. https://doi.org/10.1002/1097-0142(195311)6:6%3c1238::aid-cncr2820060618%3e3.0.co;2-6 [published Online First: 1953/11/01].

55.

Henze E, Schelbert HR, Collins JD, et al. Lymphoscintigraphy with Tc-99m-labeled dextran. J Nucl Med. 1982;23(10):923–9 [published Online First: 1982/10/01].

56.

Weissleder H, Weissleder R. Lymphedema: evaluation of qualitative and quantitative lymphoscintigraphy in 238 patients. Radiology. 1988;167(3):729–35. https://doi.org/10.1148/radiology.167.3.3363131 [published Online First: 1988/06/01].

57.

Szuba A, Shin WS, Strauss HW, et al. The third circulation: radionuclide lymphoscintigraphy in the evaluation of lymphedema. J Nucl Med. 2003;44(1):43–57 [published Online First: 2003/01/08].

58.

Devoogdt N, Van den Wyngaert T, Bourgeois P, et al. Reproducibility of lymphoscintigraphic evaluation of the upper limb. Lymphat Res Biol. 2014;12(3):175–84. https://doi.org/10.1089/lrb.2013.0034.CrossRefPubMed

59.

Aldrich MB, Guilliod R, Fife CE, et al. Lymphatic abnormalities in the normal contralateral arms of subjects with breast cancer-related lymphedema as assessed by near-infrared fluorescent imaging. Biomed Opt Express. 2012;3(6):1256–65. https://doi.org/10.1364/boe.3.001256 [published Online First: 2012/06/29].

60.

Thomis S, Dams L, Fourneau I, et al. Correlation Between Clinical Assessment And Lymphofluoroscopy In Patients With Breast Cancer-Related Lymphedema: A Study Of Concurrent Validity. Lymphat Res Biol. 2020. https://doi.org/10.1089/lrb.2019.0090 [published Online First: 2020/03/27].

61.

Devoogdt N, Pans S, De Groef A, et al. Postoperative evolution of thickness and echogenicity of cutis and subcutis of patients with and without breast cancer-related lymphedema. Lymphat Res Biol. 2014;12(1):23–31. https://doi.org/10.1089/lrb.2013.0028.CrossRefPubMed

62.

Naouri M, Samimi M, Atlan M, et al. High-resolution cutaneous ultrasonography to differentiate lipoedema from lymphoedema. Br J Dermatol. 2010;163(2):296–301. https://doi.org/10.1111/j.1365-2133.2010.09810.x [published Online First: 2010/04/23].

63.

Nelzen O, Bergqvist D, Lindhagen A. The prevalence of chronic lower-limb ulceration has been underestimated: results of a validated population questionnaire. Br J Surg. 1996;83(2):255–8. [published Online First: 1996/02/01].

64.

Charpy J, Audier M. Les troubles trophiques des membres inférieurs d’orgine veineuse: Masson. 1956.

65.

Eklof B, Rutherford RB, Bergan JJ, et al. Revision of the CEAP classification for chronic venous disorders: consensus statement. J Vasc Surg. 2004;40(6):1248–52. https://doi.org/10.1016/j.jvs.2004.09.027 [published Online First: 2004/12/29].

66.

Callam MJ, Ruckley CV, Harper DR, et al. Chronic ulceration of the leg: extent of the problem and provision of care. Br Med J (Clin Res Ed). 1985;290(6485):1855–6. https://doi.org/10.1136/bmj.290.6485.1855 [published Online First: 1985/06/22].

67.

Burnand KG, Whimster I, Naidoo A, et al. Pericapillary fibrin in the ulcer-bearing skin of the leg: the cause of lipodermatosclerosis and venous ulceration. Br Med J (Clin Res Ed). 1982;285(6348):1071–2. https://doi.org/10.1136/bmj.285.6348.1071 [published Online First: 1982/10/16].

68.

Maessen-Visch MB, Neumann HAM, Koedam MI, et al. Répercussions de l’atrophie blanche sur les patients atteints d’un ulcus cruris venosum. Phlébologie. 1997;50:367–70.

69.

Van der Veer G, Eekhof JAH, Walma EP, et al. NHG-standaarden voor de huisarts I: Elsevier/Bunge; 1999. pag. 349–55.

70.

Püschel K, Hoops E, Lignitz E. Fatale blutungen aus unterschenkelvarizes. Phlebol u Proktol. 1987;16:162.

71.

Chiesa R, Marone EM, Limoni C, et al. Chronic venous disorders: correlation between visible signs, symptoms, and presence of functional disease. J Vasc Surg. 2007;46(2):322–30. https://doi.org/10.1016/j.jvs.2007.04.030 [published Online First: 2007/06/30].

72.

Vuylsteke ME, Thomis S, Guillaume G, et al. Epidemiological study on chronic venous disease in Belgium and Luxembourg: prevalence, risk factors, and symptomatology. Eur J Vasc Endovasc Surg. 2015;49(4):432–9. https://doi.org/10.1016/j.ejvs.2014.12.031 [published Online First: 2015/02/24].

73.

Cornu-Thenard A, Boivin P, Baud JM, et al. Importance of the familial factor in varicose disease. Clinical study of 134 families. J Dermatol Surg Oncol. 1994;20(5):318–26. https://doi.org/10.1111/j.1524-4725.1994.tb01631.x [published Online First: 1994/05/01].

74.

Richtlijn ‘Diepe veneuze trombose en longembolie’: Kwaliteitsinstituut voor de gezondheidszorg CBO, 1999:26.

75.

May R, Thurner J. The cause of the predominantly sinistral occurrence of thrombosis of the pelvic veins. Angiology. 1957;8(5):419–27. https://doi.org/10.1177/000331975700800505 [published Online First: 1957/10/01].

76.

Kappert A. Phlegmasia coerulea dolens. Bern, Huber: Hringer H. Akute tiefe Becken- und Beinvenenthrombosen; 1977.

77.

Feuerstein W. Die diagnose des postthrombotischen syndroms. Phlebol u Proktol. 1979;8.

78.

Lochner J, Agathos M, Geier J, et al. Die Bedeutung von Kontaktallergien bei der Behandlung alterer Menschen mit Stauungsdermatitis. Phlebologie. 1997;26:111–4.

79.

Cavezzi A, Labropoulos N, Partsch H, et al. Duplex ultrasound investigation of the veins in chronic venous disease of the lower limbs–UIP consensus document. Part II. Anatomy. Eur J Vasc Endovasc Surg. 2006;31(3):288–99. https://doi.org/10.1016/j.ejvs.2005.07.020 [published Online First: 2005/10/19].

80.

Kurstjens RL, De Wolf MA, Alsadah SA, et al. The value of hemodynamic measurements by air plethysmography in diagnosing venous obstruction of the lower limb. J Vasc Surg Venous Lymphat Disord. 2016;4(3):313–9. https://doi.org/10.1016/j.jvsv.2016.01.005 [published Online First: 2016/06/19].

81.

Peschen M, Vanscheidt W, Sigmund G, et al. Computertomographische und magnetresonanzttomographische Untersuchungen vor und nach paratibialer Fasziotomie. Hautarzt. 1996;47(7):521–5.CrossRef

82.

Wittens C, Davies AH, Baekgaard N, et al. Editor’s choice – management of chronic venous disease: clinical practice guidelines of the european society for vascular surgery (ESVS). Eur J Vasc Endovasc Surg. 2015;49(6):678–737. https://doi.org/10.1016/j.ejvs.2015.02.007 [published Online First: 2015/04/30].

83.

Conte MS, Pomposelli FB. Society for vascular surgery practice guidelines for atherosclerotic occlusive disease of the lower extremities management of asymptomatic disease and claudication. Introduction. J Vasc Surg. 2015;61(3 Suppl):1S. https://doi.org/10.1016/j.jvs.2014.12.006 [published Online First: 2015/02/28].

84.

Conte MS, Bradbury AW, Kolh P, et al. Global vascular guidelines on the management of chronic limb-threatening ischemia. Eur J Vasc Endovasc Surg. 2019;58(1S):S1–S109 e33. https://doi.org/10.1016/j.ejvs.2019.05.006 [published Online First: 2019/06/12].

85.

Richtlijn Perifeer Arterieel Vaatlijden (PAV). In: (FMS) FMs, ed. Nederland, 2016.

86.

Hardman RL, Jazaeri O, Yi J, et al. Overview of classification systems in peripheral artery disease. Semin Intervent Radiol. 2014;31(4):378–88. https://doi.org/10.1055/s-0034-1393976 [published Online First: 2014/12/02].

87.

Lavrijsen APM, Damstra RJ, Van Dissel JT, et al. Richtlijn cellulitis en erysipelas van de onderste extremiteiten. 2013. [Available from: https://www.alii.care//engine/download/blob/alii/470/2019/41/20190717_richtlijn-erysipelas-en-cellulitis-definitief.pdf?app=alii&class=74&id=2159&field=470 [last accessed 22-1-2019]].

88.

Chlebicki MP, Oh CC. Recurrent cellulitis: risk factors, etiology, pathogenesis and treatment. Curr Infect Dis Rep. 2014;16(9):422. https://doi.org/10.1007/s11908-014-0422-0 [published Online First: 2014/07/02].

89.

Goettsch WG, Bouwes Bavinck JN, Herings RM. Burden of illness of bacterial cellulitis and erysipelas of the leg in the Netherlands. J Eur Acad Dermatol Venereol. 2006;20(7):834–9. https://doi.org/10.1111/j.1468-3083.2006.01657.x [published Online First: 2006/08/11].

90.

Cranendonk DR, Lavrijsen APM, Prins JM, et al. Cellulitis: current insights into pathophysiology and clinical management. Neth J Med. 2017;75(9):366–78 [published Online First: 2017/12/09].

91.

Bartholomeeusen S, Vandenbroucke J, Truyers C, et al. Epidemiology and comorbidity of erysipelas in primary care. Dermatology. 2007;215(2):118–22. https://doi.org/10.1159/000104262 [published Online First: 2007/08/09].

92.

Inghammar M, Rasmussen M, Linder A. Recurrent erysipelas–risk factors and clinical presentation. BMC Infect Dis. 2014;14:270. https://doi.org/10.1186/1471-2334-14-270 [published Online First: 2014/06/03].

93.

Eells SJ, Chira S, David CG, et al. Non-suppurative cellulitis: risk factors and its association with Staphylococcus aureus colonization in an area of endemic community-associated methicillin-resistant S. aureus infections. Epidemiol Infect. 2011;139(4):606–12. https://doi.org/10.1017/s0950268810001408 [published Online First: 2010/06/22].

94.

Levell NJ, Wingfield CG, Garioch JJ. Severe lower limb cellulitis is best diagnosed by dermatologists and managed with shared care between primary and secondary care. Br J Dermatol. 2011;164(6):1326–8. https://doi.org/10.1111/j.1365-2133.2011.10275.x [published Online First: 2011/05/14].

95.

Strazzula L, Cotliar J, Fox LP, et al. Inpatient dermatology consultation aids diagnosis of cellulitis among hospitalized patients: A multi-institutional analysis. J Am Acad Dermatol. 2015;73(1):70–5. https://doi.org/10.1016/j.jaad.2014.11.012 [published Online First: 2015/06/20].

96.

Weng QY, Raff AB, Cohen JM, et al. Costs and consequences associated with misdiagnosed lower extremity cellulitis. JAMA Dermatol. 2016. https://doi.org/10.1001/jamadermatol.2016.3816.CrossRefPubMed

97.

Hirschmann JV, Raugi GJ. Lower limb cellulitis and its mimics: part II. Conditions that simulate lower limb cellulitis. J Am Acad Dermatol. 2012;67(2):177 e1–9; quiz 85–6. https://doi.org/10.1016/j.jaad.2012.03.023 [published Online First: 2012/07/17].

98.

Monitoring and epidemiological assessment of mass drug administration in the global programme to eliminate lymphatic filariasis: a manual for national elimination programmes. In: Organization WH, ed. Geneva; 2011.

99.

WHO. Lymphatic Filariasis report 2019.

100.

Organization WH. Guideline: alternative mass drug administration regimens to eliminate lymphatic filariasis; Licence: CC BY-NC-SA 3.0 IGO, 2017.

101.

Dreyer G, Noroes J, Figueredo-Silva J, et al. Pathogenesis of lymphatic disease in bancroftian filariasis: a clinical perspective. Parasitol Today. 2000;16(12):544–8. https://doi.org/10.1016/s0169-4758(00)01778-6 [published Online First: 2000/12/21].

102.

Pani SP, Srividya A. Clinical manifestations of bancroftian filariasis with special reference to lymphoedema grading. Indian J Med Res. 1995;102:114–8 [published Online First: 1995/09/01].

103.

Olszewski WL, Jamal S, Manokaran G, et al. Skin changes in filarial and non-filarial lymphoedema of the lower extremities. Trop Med Parasitol. 1993;44(1):40–4. [published Online First: 1993/03/01].

104.

Davey G, Tekola F, Newport MJ. Podoconiosis: non-infectious geochemical elephantiasis. Trans R Soc Trop Med Hyg. 2007;101(12):1175–80. https://doi.org/10.1016/j.trstmh.2007.08.013 [published Online First: 2007/11/03].

105.

Price E. Podoconiosis: non-filarial Elephantiasis. Oxford: Oxford Medical; 1990.

106.

Price EW, Henderson WJ. The elemental content of lymphatic tissues of barefooted people in Ethiopia, with reference to endemic elephantiasis of the lower legs. Trans R Soc Trop Med Hyg. 1978;72(2):132–6. https://doi.org/10.1016/0035-9203(78)90048-2 [published Online First: 1978/01/01].

107.

Wendemagegn E, Tirumalae R, Boer-Auer A. Histopathological and immunohistochemical features of nodular podoconiosis. J Cutan Pathol. 2015;42(3):173–81. https://doi.org/10.1111/cup.12441 [published Online First: 2014/11/18].

108.

Tekola-Ayele F, Wendemagegn E. Podoconiosis: tropical lymphedema of the lower legs. In: Ltd iP, ed. Dermatology and allergology – principles and practice. Hong Kong; 2014.

109.

Sikorski C, Ashine M, Zeleke Z, et al. Effectiveness of a simple lymphoedema treatment regimen in podoconiosis management in southern ethiopia: one year follow-up. PLoS Negl Trop Dis. 2010;4(11):e902. https://doi.org/10.1371/journal.pntd.0000902 [published Online First: 2010/12/15].

110.

Griffiths C, Barker J, Bleiker T, et al. Rook’s textbook of dermatology; 9th revised edition: Wiley & sons; 2016.

Titel: Medische diagnostiek
Auteurs: Robert Damstra, PhD, MD
Kristiana Gordon, PhD, MD
Malou van Zanten, PhD, PT
Sahar Mansour, PhD, MD
Kirsten van Duinen, MD
Sarah Thomis, MSc
Nele Devoogdt, PhD, PT
Inge Fourneau, PhD, MD
Sjan Lavrijsen, PhD, MD
Wendemagegn Enbiale, MD
Michette de Rooij, PhD, MD
Uitgeverij: Bohn Stafleu van Loghum
Boek: Oedeem en oedeemtherapie
Print ISBN: 978-90-368-2589-4

Elektronisch ISBN: 978-90-368-2590-0

Copyright: 2021
DOI: https://doi.org/10.1007/978-90-368-2590-0_2

Bohn Stafleu van Loghum

Deel dit onderdeel of sectie (kopieer de link)

Samenvatting

Log in om toegang te krijgen